SimBioSys Receives FDA Clearance for AI-Enhanced TumorSight Viz with Clinical Decision Support
核心洞察
SimBioSys (搜索) has obtained its second FDA 510(k) clearance for TumorSight Viz (搜索), expanding its utility for breast surgeons with AI-driven enhancements.
The updated TumorSight Viz (搜索) features rapid AI image processing, improved tumor segmentation, direct MRI access via PACS, and clinical decision support (CDS).
The CDS application is designed to aid treatment planning and optimize surgical decisions for early-stage breast cancer (搜索) patients, aligning with NCCN guidelines.
SimBioSys (搜索), a TechBio company focused on digital precision medicine for cancer care, announced its second FDA 510(k) clearance for TumorSight Viz (搜索), designed to enhance breast cancer (搜索) surgery planning. The updated platform now includes AI-driven tumor segmentation, rapid image processing, seamless MRI access, and a clinical decision support (CDS) feature.
The new CDS application is designed to provide data-driven insights for informing breast surgeons' planning and preparation for surgery. This aims to optimize treatment decisions for early-stage breast cancer (搜索) patients undergoing surgery.
Enhanced Capabilities of TumorSight Viz
TumorSight Viz (搜索) now incorporates several key enhancements:
- Enhanced AI-Driven Segmentation: Utilizes AI to deliver accurate and efficient tumor and tissue segmentation, enabling detailed 3D spatial visualization to support treatment planning.
- Clinical Decision Support (CDS) Application: The new CDS application is designed to provide data-driven insights for informing breast surgeons' planning and preparation for surgery.
- Direct MRI Access via PACS Systems: TumorSight Viz now supports integration with middleware software as well as direct to PACS systems, allowing automated access to MRI images for analysis within the TumorSight platform and seamless fit into the clinician workflow.
Clinical Impact and Alignment with Guidelines
Recent NCCN guideline updates emphasize individualized, data-supported treatment planning to support breast reconstruction and oncoplastic surgery as safe and effective options for eligible patients. TumorSight Viz (搜索) aligns with these recommendations by enabling volume and anatomical measurements that assist surgeons in utilizing volume displacement techniques with a goal to achieve optimal cosmetic and functional outcomes. With the new CDS capability, surgeons are now better equipped with output measurements from TumorSight Viz that are aligned with standard of care guidelines to help plan lumpectomies more precisely, supporting both effective tumor removal and preservation of breast appearance.
According to Dr. Freya Schnabel from NYU, "TumorSight Viz (搜索)'s clinical decision support functionality provides a groundbreaking resource to assist breast surgeons and oncologists in considering the best possible approaches for each patient, fostering shared decision-making and precision care."
Addressing Breast Cancer Care Needs
With over 300,000 patients affected by breast cancer (搜索) annually in the U.S., SimBioSys (搜索)'s enhanced TumorSight platform aims to provide surgeons and patients with greater confidence in treatment decisions. The platform combines AI-driven visualizations with CDS tools to support more informed choices.
"This second FDA clearance represents a significant milestone in our mission to redefine precision medicine for cancer," said Barry Rosen, MD, Chief Medical Officer at SimBioSys (搜索). "TumorSight Viz (搜索)'s latest capabilities elevate the standard of breast cancer (搜索) care by allowing surgeons to make more informed choices, moving closer to an era of precision surgery that reduces variation and supports breast conservation when desired by the patient."